Where does Aurinia Pharmaceuticals's cash flow data come from?

Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	$287.2M+4,893%	$5.75M+107%	-$78.02M+27.9%	-$108.18M+40.2%
Depreciation and amortization	$19.45M0.0%	$19.45M+67.0%	$11.65M+330%	$2.71M+48.8%
Stock-based compensation	$14.68M-53.5%	$31.6M-30.3%	$45.31M+40.3%	$32.3M+3.4%
Deferred income taxes	——	$0—	$0—	——
Change in inventories	——	——	$15.87M+74.9%	$9.07M+60.7%
Change in accounts payable	——	——	——	——
Change in accrued liabilities	——	$13.33M+9.7%	$12.15M+715%	$1.49M—
Other working capital changes	$200K—	——	——	$1.61M+80,500%
Change in deferred revenue	——	$5.79M+53.8%	$3.76M+23.5%	$3.05M—
Change in prepaid expenses	——	——	——	——
Change in operating lease liabilities	-$802K-6.9%	-$750K-11.4%	-$673K-3.2%	-$652K—
Change in receivables	$5.17M—	——	——	-$1.93M-113%
Net cash from operating activities	$135.66M+206%	$44.39M—	——	——
Net cash from investing activities	——	——	-$6.71M—	——
Repurchases of common stock	$98.16M+144%	$40.24M—	$0—	$0—
Proceeds from issuance of common stock	——	——	——	$1.91M-99.0%
Payments for finance leases	$15.91M+7.7%	$14.77M+47.3%	$10.03M—	——
Taxes paid for net share settlement	$9.76M+59.2%	$6.13M+169%	$2.28M+119%	$1.04M—
Net cash from financing activities	-$106.11M-116%	-$49.09M-857%	-$5.13M-311%	$2.43M-98.9%
Net increase (decrease) in cash	——	$34.56M+172%	-$47.78M—	——
Income taxes paid	$3.09M+41.6%	$2.18M+340%	$496K-74.9%	$1.98M—
Accretion (Amortization) of Discounts and Premiums, Investments	$10.18M-20.0%	$12.73M+4.9%	$12.14M+672%	$1.57M+338%
Foreign Translation Gain (Loss) On Revaluation Of Finance Lease Liability	-$9.69M—	——	-$5.95M—	$0—
Accrued expenses and other liabilities	——	$13.33M+9.7%	$12.15M+715%	$1.49M—
Operating lease liabilities	-$802K-6.9%	-$750K-11.4%	-$673K-3.2%	-$652K—
Increase (Decrease) in Prepaid Expense	——	——	——	——
Other Noncash Income (Expense)	$200K—	——	——	$1.61M+80,500%
Payments To Acquire Other Productive Assets	$252K-10.3%	$281K—	——	$292K—
Finance Lease, Principal Payments	$15.91M+7.7%	$14.77M+47.3%	$10.03M—	——
Increase Decrease In Contract With Customer Liability	——	$5.79M+53.8%	$3.76M+23.5%	$3.05M—
Increase Decrease In Operating Lease Liability	-$802K-6.9%	-$750K-11.4%	-$673K-3.2%	-$652K—
Taxes withheld related to vesting of performance awards	$3.77M—	$0—	$0—	——
Income Taxes Paid, Net	$3.09M+41.6%	$2.18M+340%	$496K-74.9%	$1.98M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Aurinia Pharmaceuticals's cash flow data come from?: Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.